María Luz Couce Pico-rekin lankidetzan egindako argitalpenak (20)

2021

  1. Evaluation of body composition, physical activity, and food intake in patients with inborn errors of intermediary metabolism

    Nutrients, Vol. 13, Núm. 6

  2. Letter to the editor concerning the article ‘Safety of vaccines administration in hereditary fructose intolerance’

    Human Vaccines and Immunotherapeutics

  3. Reply letter to “safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance”

    Human Vaccines and Immunotherapeutics

2020

  1. Clinical utility of lct genotyping in children with suspected functional gastrointestinal disorder

    Nutrients, Vol. 12, Núm. 10, pp. 1-16

  2. Effects of nutritional education interventions on metabolic risk in children and adolescents: A systematic review of controlled trials

    Nutrients, Vol. 12, Núm. 1

  3. Effects of prebiotic and probiotic supplementation on lactase deficiency and lactose intolerance: A systematic review of controlled trials

    Nutrients, Vol. 12, Núm. 5

2019

  1. Effects of LC-PUFA supplementation in patients with phenylketonuria: A systematic review of controlled trials

    Nutrients, Vol. 11, Núm. 7

  2. Identification and characterization of new variants in FOXRED1 gene expands the clinical spectrum associated with mitochondrial complex I deficiency

    Journal of Clinical Medicine, Vol. 8, Núm. 8

2018

  1. Carbohydrate status in patients with phenylketonuria

    Orphanet Journal of Rare Diseases, Vol. 13, Núm. 1

  2. Early cardiac abnormalities in obese children and their relationship with adiposity

    Nutrition, Vol. 46, pp. 83-89

  3. Effects of Dairy Product Consumption on Height and Bone Mineral Content in Children: A Systematic Review of Controlled Trials

    Advances in nutrition (Bethesda, Md.), Vol. 10, Núm. 2, pp. S88-S96

  4. V232D mutation in patients with cystic fibrosis Not so rare, not so mild

    Medicine (United States), Vol. 97, Núm. 28

2017

  1. Arterial stiffness assessment in patients with phenylketonuria

    Medicine (United States), Vol. 96, Núm. 51

2016

  1. Lipid profile status and other related factors in patients with Hyperphenylalaninaemia

    Orphanet Journal of Rare Diseases, Vol. 11, Núm. 1

2015

  1. Corrigendum to "Risk factors for developing mineral bone disease in phenylketonuric patients" [Mol. Genet. Metab. 108 (2013) 149-154]

    Molecular Genetics and Metabolism

  2. Micronutrient in hyperphenylalaninemia

    Data in Brief

  3. New insights in growth of phenylketonuric patients

    European Journal of Pediatrics, Vol. 174, Núm. 5, pp. 651-659

  4. Utilidad de los marcadores de remodelado óseo en la detección de enfermedad mineral ósea en pacientes con fenilcetonuria

    Medicina Clinica, Vol. 144, Núm. 5, pp. 193-197

  5. Vitamin and mineral status in patients with hyperphenylalaninemia

    Molecular Genetics and Metabolism, Vol. 115, Núm. 4, pp. 145-150

2013

  1. Risk factors for developing mineral bone disease in phenylketonuric patients

    Molecular Genetics and Metabolism, Vol. 108, Núm. 3, pp. 149-154